High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea
2014 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 58, no 9, 5585-5588 p.Article in journal (Refereed) Published
We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clinical gonococcal isolates and international reference strains (n = 250), including strains with diverse multidrug resistance and extensive drug resistance. The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials. AZD0914 should be further evaluated, including in vitro selection, in vivo emergence and mechanisms of resistance, pharmacokinetics/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clinical trials.
Place, publisher, year, edition, pages
American Society for Microbiology , 2014. Vol. 58, no 9, 5585-5588 p.
Microbiology in the medical area Pharmacology and Toxicology
IdentifiersURN: urn:nbn:se:oru:diva-56454DOI: 10.1128/AAC.03090-14ISI: 000341262700070PubMedID: 24982070ScopusID: 2-s2.0-84906090956OAI: oai:DiVA.org:oru-56454DiVA: diva2:1082412
Örebro County Council Research Committee
Foundation for Medical Research at Örebro University Hospital, Sweden
Infection iMed, AstraZeneca Pharmaceuticals LP, Waltham, MA2017-03-162017-03-162017-03-16Bibliographically approved